Clinical Trials at MD Anderson Cancer Center
As of August 2026, 387 paid clinical trials are recruiting at MD Anderson Cancer Center, located at 1515 HOLCOMBE BLVD, UNIT 1445, HOUSTON, TX 77030-4000, phone (713) 745-0496 in Houston, Texas. Active studies at this site cover conditions such as Breast Cancer, Acute Myeloid Leukemia and Advanced Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Houston
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
389 clinical trials at MD Anderson Cancer Center
·Clear filters·A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
CAR-T Long Term Follow Up (LTFU) Study
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Common conditions studied in Houston
- Breast Cancer (79 active studies)
- Acute Myeloid Leukemia (54 active studies)
- Advanced Solid Tumor (53 active studies)
- Ovarian Cancer (47 active studies)
- Colorectal Cancer (45 active studies)
- Prostate Cancer (43 active studies)
Leading research sponsors in Houston
- M.D. Anderson Cancer Center
- The University of Texas Health Science Center, Houston
- Baylor College of Medicine
- AstraZeneca
- The Methodist Hospital Research Institute
Frequently asked questions
How many paid clinical trials are currently recruiting in Houston?
There are approximately 3,038 recruiting clinical trials in Houston, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Houston pay participants?
Most recruiting trials in Houston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Houston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Houston?
The most common conditions under active study in Houston include Breast Cancer (79), Acute Myeloid Leukemia (54), Advanced Solid Tumor (53), Ovarian Cancer (47), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Houston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Houston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Houston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Houston?
Recruiting research sites in Houston include MD Anderson Cancer Center, M D Anderson Cancer Center, Baylor College of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Houston right now?
The largest active categories in Houston are Cancer & tumors (1,191), Neurology & pain (145), Diabetes & metabolic (103). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of MD Anderson Cancer Center?
MD Anderson Cancer Center is located at 1515 HOLCOMBE BLVD, UNIT 1445, HOUSTON, TX 77030-4000. Use the Google Maps link in the intro above to get directions.
How do I contact MD Anderson Cancer Center?
You can reach MD Anderson Cancer Center by phone at (713) 745-0496. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.